Skip to main content
Search

Advantages of using monolithic silica gel columns in the pharma industry: biomolecule separation

Part 2 of 2
Published on August 29, 2021   29 min

A selection of talks on Methods

Please wait while the transcript is being prepared...
0:00
Hello, I'm Egidijus Machtejevas. I'm Lead Expert in Chromatography Product and Portfolio Management at Merck in Darmstadt. Today, we have a part 2 talk about the advantages of using monolithic silica gel columns in the pharmaceutical industry. Our focus topic today is biomolecule separation.
0:23
First of all, I would like to give you a short introduction about the bioseparation itself and about our new wide pore monolithic column products.
0:34
Today, we have a new era in the pharmaceutical industry. In the past, some years ago, like 20 or more years ago, 90 percent of all therapeutics had been small molecules. However, today's situation is different and we have a very clear focus on therapeutics, which are large molecules. These large molecules provide certain advantages, like a delivery to target cells and tissues, with less serious side effects. But in terms of chromatography, small molecules and large molecules differ quite significantly. Of course, small molecules are small and large molecules, they are much more complex and they are big in size. Last but not least, they have quite a number of different functionalization on the surface.
1:25
How would the chromatographic material be different to accommodate these large molecules? In this case, we have to have larger pores and there is a very simple general rule. The pore size must be about 10 times bigger than the Stokes radius of your molecule in order for the big molecule not to feel the size exclusion effect.
Show
Hide

Advantages of using monolithic silica gel columns in the pharma industry: biomolecule separation

Embed in course/own notes